Clinical Trial Update: A Phase 3 Study of a Daclatasvir/Asunaprevir/BMS-791325 Fixed Dose Combination (FDC) in Subjects With Chronic Hepatitis C Genotype 1 [Phase 3]

View source ↗

Summary

Phase 3 trial of a fixed-dose combination (daclatasvir/asunaprevir/BMS-791325) for chronic hepatitis C genotype 1 has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Asunaprevir (asunaprevir)
• BMS-791325
• Daclatasvir (daclatasvir)
• Daclatasvir/Asunaprevir/BMS-791325 Fixed Dose Combination

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Hepatitis C Virus | Phase 3 | Status: COMPLETED | Results posted: 2019-08-16